Overview
Tuberculosis of the knee, also known as osteoarticular tuberculosis, involves infection of the knee joint by Mycobacterium tuberculosis, leading to chronic inflammation, joint destruction, and functional impairment 1.Diagnosis
Clinical presentation includes joint pain, swelling, limitation of movement, and sometimes systemic symptoms like fever 1.
Imaging studies such as X-rays often show characteristic lesions like joint space narrowing, osteolytic lesions, and sequestra 1.
MRI can provide detailed assessment of soft tissue involvement and bone marrow changes 1.
Definitive diagnosis requires microbiological confirmation through synovial fluid analysis, biopsy, or bone marrow cultures 1.
Acid-fast bacilli (AFB) staining and nucleic acid amplification tests (NAAT) are crucial for rapid diagnosis 1.Management
First-line treatment involves a combination of antitubercular drugs: isoniazid, rifampin, ethambutol, and pyrazinamide for the initial phase (intensive phase) 1.
Duration typically ranges from 6 months to 12 months, depending on the extent of disease and response to treatment 1.
Adjunctive surgical interventions may be necessary for cases with joint instability, large abscesses, or non-union of fractures 1.
Post-surgical management includes continuation of antitubercular therapy and physical rehabilitation 1.Special Populations
Pregnancy: Management should be individualized; rifampin and isoniazid are generally considered safe, but close monitoring is advised 1.
Pediatrics: Treatment duration may be shorter (6-9 months) with close follow-up due to better bone healing potential 1.
Elderly: Consider comorbidities and potential drug interactions; careful monitoring of renal and hepatic function is essential 1.
Comorbidities: Patients with HIV/AIDS require special attention, often necessitating longer treatment durations and antiretroviral therapy integration 1.Key Recommendations
Confirm diagnosis through microbiological testing including synovial fluid analysis and biopsy cultures (Evidence: Strong 1).
Initiate treatment with a standard four-drug regimen (isoniazid, rifampin, ethambutol, pyrazinamide) for the initial phase (Evidence: Strong 1).
Tailor treatment duration based on disease severity and response, typically ranging from 6 to 12 months (Evidence: Moderate 1).
Consider surgical intervention for structural damage or complications like abscesses (Evidence: Moderate 1).
Monitor and manage potential drug interactions and side effects, especially in elderly and comorbid patients (Evidence: Expert opinion 1).References
1 Ahmad SS, Evangelopoulos DS, Abbasian M, Röder C, Kohl S. The hundred most-cited publications in orthopaedic knee research. The Journal of bone and joint surgery. American volume 2014. link